Moteur de recherche d’entreprises européennes
Financement de l’UE (6 000 000 €) : Une immunothérapie de nouvelle génération pour le cancer du col de l’utérus induit par le virus du papillome humain Hor01/12/2017 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Une immunothérapie de nouvelle génération pour le cancer du col de l’utérus induit par le virus du papillome humain
Cervical cancer (CxCa) is caused by high risk types of the human papillomavirus (a.o. HPV16). Prophylactic HPV vaccination is not the standard of care in all European countries, and where approved it is not sufficiently adopted. Once infected, these vaccines no longer prevent premalignant lesions and CxCa, which can only be treated with surgery or radio-chemotherapy. However, this is not effective in recurrent/advanced CxCa. In underdeveloped countries, CxCa is often detected when it is too late for curative treatment. With an estimated global incidence of 500.000 new cases of CxCa and 274.000 deaths per year, the need for an effective therapy is extremely high. Targeted immunotherapy is an effective approach to induce a tumour-directed immune response. Previously, members of the IMMUNISA consortium have formulated ISA101, a cancer vaccine consisting of overlapping synthetic long peptides covering all epitopes of the HPV16 oncogenic proteins. ISA101 has shown promising Phase 1 clinical trial results in patients with advanced CxCa where it works synergistically with chemotherapy. IMMUNISA now proposes the multi-centre randomised Phase 2 CervISA-2 trial; a careful assessment of the efficacy of the proprietary ISA101b therapeutic vaccine in combination with chemotherapy for the treatment of CxCa, measured by a prolonged progression free survival. A multidisciplinary collaboration between leading clinical EU sites specialised in CxCa, a partner providing strategic and operational regulatory service and a cutting-edge biotech SME will enable the optimal implementation of the CervISA-2 trial, exploitation activities and overall project dissemination. This is pivotal to catapult further development of ISA101b as a commercial vaccine and push it towards clinical implementation as fast as possible. For ISA101b, IMMUNISA will provide, 1) clinical data on the efficacy, 2) a solid exploitation strategy and 3) the regulatory framework for efficient translation to clinical use.
| European Cancer Patient Coalition | 30 250 € |
| GRANZER HEINZ ULRICH | 267 188 € |
| INC Research UK Ltd. | 3 368 802 € |
| Isa Therapeutics B.V. | 1 653 010 € |
| Katholieke Universiteit Leuven | 496 875 € |
| 183 875 € |
https://cordis.europa.eu/project/id/731623
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
Les visualisations de "European Cancer Patient Coalition - Financement de l’UE (6 000 000 €) : Une immunothérapie de nouvelle génération pour le cancer du col de l’utérus induit par le virus du papillome humain"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
